Search
Advertisement
From ₹9 crore to ₹2.5 lakh: How a mother’s plea sparked a Hyderabad doctor’s rare drug cost fight

From ₹9 crore to ₹2.5 lakh: How a mother’s plea sparked a Hyderabad doctor’s rare drug cost fight

AHDS is a rare genetic disorder caused by a defect in the MCT8 thyroid hormone transporter. The defect prevents thyroid hormone from entering brain cells during critical stages of early development, while simultaneously allowing excess triiodothyronine (T3) to flood the rest of the body.

Business Today Desk
Business Today Desk
  • Updated Nov 21, 2026 8:53 AM IST
From ₹9 crore to ₹2.5 lakh: How a mother’s plea sparked a Hyderabad doctor’s rare drug cost fightThe initiative was spearheaded by Hyderabad-based paediatrician Dr. Sivaranjani Santosh alongside Access to Medicines India.

An Instagram direct message and a WhatsApp text from desperate parents set off a cross-border medical effort that has slashed the annual cost of a life-sustaining rare disease drug from as much as ₹9 crore to ₹2.5 lakh per child. On November 30, 2026, seven Indian children diagnosed with Allan-Herndon-Dudley syndrome (AHDS) will receive a full year’s supply of the drug tiratricol completely free of cost.

Advertisement

The initiative was spearheaded by Hyderabad-based paediatrician Dr. Sivaranjani Santosh alongside Access to Medicines India. For families navigating AHDS — also known as MCT8 deficiency — the barrier to survival has long been financial rather than scientific.

In commercial markets, such as the United States, the branded version of tiratricol (Emcitate) costs roughly $950,000, placing annual treatment between ₹4.68 crore and ₹9 crore per patient.

Understanding the condition

AHDS is a rare genetic disorder caused by a defect in the MCT8 thyroid hormone transporter. The defect prevents thyroid hormone from entering brain cells during critical stages of early development, while simultaneously allowing excess triiodothyronine (T3) to flood the rest of the body.

Left untreated, children face severe developmental delays, intellectual disability, low muscle tone, uncoordinated movements, a racing heart, and eventual cardio-respiratory failure. Tiratricol, also referred to as TRIAC, mimics thyroid hormone to bypass the defective transporter and protect the brain.

Advertisement

A parent's plea triggers action The push began when Pavitra, the mother of a young patient named Aarav under Dr. Sivaranjani’s care, struggled to sustain the ₹12 lakh to ₹13 lakh monthly cost of importing the medication from Germany.

After parents reached out via social media, Dr. Sivaranjani collaborated with KM Gopakumar of Access to Medicines India and launched a public advocacy campaign to find a sustainable alternative.

Advertisement

Compounding breakthrough

When efforts to secure support from commercial manufacturer Egetis Therapeutics fell through — a moment Dr. Sivaranjani described on X as a "huge set back" — the team turned to pharmaceutical compounding.

With backing from the Netherlands-based Pharmaceutical Accountability Foundation (PAF), the Transvaal Pharmacy in The Hague formulated the active pharmaceutical ingredient at an average annual cost of ₹2.5 lakh per child. Crowdfunding from PAF and generous donations from the parents of Dr. Sivaranjani’s own patients covered the expenses entirely, ensuring the seven families pay nothing.

Coordinating across borders Bringing the medicine to India required navigating strict regulatory channels:

  • Patient identification: Alongside Aarav and another child in Hyderabad, five patients were identified through Dr. Praveen and specialists at Christian Medical College (CMC) in Vellore, with a seventh child joining after a public appeal. 
  • Regulatory clearance: The Organization for Rare Diseases India (ORDI) assisted families in securing individual import permits, with Aarav’s mother Pavitra stepping in to guide other parents through the paperwork — becoming what Dr. Sivaranjani called "a proactive team member than a passive observer". 
  • Delivery schedule: Because tiratricol has a six-month shelf life, the one-year supply is arriving in two batches, with initial handovers scheduled in Hyderabad and Bengaluru on November 30. 

A call for domestic production

Advertisement

While the imported batches offer immediate relief, Dr. Sivaranjani maintains that relying on foreign pharmacies is not a permanent solution. She is now urging the Union government to step in and localise production.

"I request the government of India to ensure the active pharmaceutical ingredient is compounded in India and is made available under the National Rare Diseases Policy," she wrote on X. "We can easily prepare it here, and it would cost even less."

She has also appealed to paediatricians, endocrinologists, and neurologists across the country to share details of any children with confirmed or suspected MCT8 deficiency so they can be connected to diagnosis and treatment.

ABOUT THE AUTHOR

Business Today Desk
Business Today Desk

Business Today brings you the latest news, views and analysis from the world of finance, economy, markets, corporates, startups, tech, and the digital economy. You can find everything from breaking news to deep dives to immersive essays and more on a variety of subjects across all formats - online, magazine, television, data visualisation, et al.

Published on: Nov 21, 2026 8:53 AM IST